Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $41.60 USD
Change Today +0.43 / 1.04%
Volume 81.0K
FMS On Other Exchanges
Symbol
Exchange
Xetra
Munich
Mexico
Frankfurt
As of 8:04 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

fresenius medical care-adr (FMS) Key Developments

Fresenius Is Reportedly In Talks To Buy Nephromor

Nephromor Ltd. is slated for sale to Fresenius Medical Care AG & Co. KGAA (DB:FME) for ILS 350 million, sources inform "Globes."

Fresenius Medical Care AG & Co. KGAA to Approve Dividend for 2014

At the annual general meeting to be held on May 19, 2015, shareholders will be asked to approve a dividend of 0.78 per share, an increase of 1% from 2013 of 0.77.

Fresenius Medical Care AG & Co. KGAA Reports Audited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Years 2015 and 2016

Fresenius Medical Care AG & Co. KGAA reported audited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, net revenue increased by 12% to $4,320 million (15% at constant currency) as compared to the fourth quarter of 2013. Operating income (EBIT) increased from $661 million in the fourth quarter of 2013 to $663 million in the fourth quarter of 2014. Net income attributable to shareholders of the company was $335 million, a decrease of 4% compared to $349 million for the fourth quarter of 2013. Basic earnings per share were $1.11, a decrease of 5% compared to the corresponding number for the fourth quarter of 2013. The company generated $588 million in net cash provided by operating activities, representing 14% of revenue, almost unchanged compared to the corresponding figure of last year of $589 million. A total of $282 million was spent for capital expenditures, net of disposals. Free cash flow was $306 million compared to $355 million in the fourth quarter of 2013. EBITDA was $849 million against $830 million a year ago. Income before taxes was $546 million against $563 million a year ago. Purchases of property, plant and equipment was $285 million against $235 million a year ago. For the full year, net revenue increased by 8% to $15,832 million (10% at constant currency) as compared to the full year 2013. Operating income (EBIT) was $2,255 million as compared to $2,256 million in the full year 2013. Net income attributable to shareholders of the company was $1,045 million, down by 6% from the corresponding number of $1,110 million for the full year 2013. Basic earnings per share were $3.46, a decrease of 5% compared to the corresponding number for the full year 2013. The company generated $1,861 million in net cash provided by operating activities, representing 12% of revenue, as compared to $2,035 million for the same period in 2013. A total of $920 million was spent for capital expenditures, net of disposals. EBITDA was $2,954 million against $2,904 million a year ago. Income before taxes was $1,844 million against $1,847 million a year ago. Purchases of property, plant and equipment was $932 million against $748 million a year ago. Total debt was $9,532 million. For the full year 2015, the company expects revenue to grow at 5% to 7%, which at constant currency is a growth rate of 10% to 12%. Net income attributable to shareholders of the company is expected to increase 0% to 5%. The company expects to spend around $1.0 billion on capital expenditures and around $400 million on acquisitions in 2015. For the year 2016, the company expects an acceleration of growth with a revenue increase of 9% to 12% and net income attributable to shareholders of the company growing by 15% to 20%.

Fresenius Medical Care Mulls Acquisition

Fresenius Medical Care AG & Co. KGAA (DB:FME) is seeking acquisition. Fresenius Medical Care AG & Co. said in fourth quarter and full year 2014 results, “The company expects to spend around $1.0 billion on capital expenditures and around $400 million on acquisitions in 2015.”

Fresenius Medical Care AG & Co. KGAA Presents at UniCredit und Kepler Cheuvreux 14th German Corporate Conference, Jan-19-2015 09:45 AM

Fresenius Medical Care AG & Co. KGAA Presents at UniCredit und Kepler Cheuvreux 14th German Corporate Conference, Jan-19-2015 09:45 AM. Venue: Villa Kennedy, Kennedyallee 70, D-60596 Frankfurt, Germany. Speakers: Michael Brosnan, Chief Financial Officer of Fresenius Medical Care Management AG and Member of the Management Board for Fresenius Medical Care Management AG.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FMS:US $41.60 USD +0.43

FMS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $68.55 USD +0.53
Becton Dickinson and Co $144.59 USD +1.38
DaVita HealthCare Partners Inc $81.83 USD +0.76
Mylan NV $61.63 USD -0.25
Toray Industries Inc ¥1,036 JPY +7.00
View Industry Companies
 

Industry Analysis

FMS

Industry Average

Valuation FMS Industry Range
Price/Earnings 24.2x
Price/Sales 1.6x
Price/Book 2.7x
Price/Cash Flow 24.8x
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FRESENIUS MEDICAL CARE-ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.